AdAPT-001: the TGF-β-trap-enhanced oncolytic adenovirus

Anthony Paul Conley, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the mechanism of action AdAPT-001 and the rationale behind combining it with an immune checkpoint inhibitor for patients with immune refractory cancers. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.